How to Help Your Patients Find Olumiant in Stock: A Provider's Guide

Prescribing Olumiant (baricitinib) is the first step. Actually getting it into your patient's hands is often the harder part. Whether you're a rheumatologist, dermatologist, NP, or PA who prescribes baricitinib regularly, this guide gives you a practical framework to help patients navigate the specialty pharmacy system and access their medication.

Why Olumiant Access Is a Provider Responsibility, Not Just a Patient Problem

Olumiant is a specialty medication with limited distribution. Patients cannot simply walk into a pharmacy and pick it up. The path from your prescription pad to the patient's hand involves specialty pharmacy selection, insurance prior authorization, patient enrollment in support programs, and often multiple phone calls. Practices with dedicated support staff for specialty medications achieve faster access for patients and fewer gaps in therapy.

Step 1: Send the Prescription to the Right Specialty Pharmacy

This is the most common access failure point. Always send Olumiant prescriptions to the patient's insurance plan's designated specialty pharmacy — not the nearest retail chain. Using an out-of-network specialty pharmacy can result in claim rejection or full-price dispensing at $2,500–$3,000/month. Best practices:

Before sending the prescription, verify which specialty pharmacy the patient's insurer designates for baricitinib

For Medicare Part D patients, the designated pharmacy may differ from commercial plan patients — check each patient's specific plan

For uninsured patients, route directly to the Lilly Cares Foundation or Olumiant Together program before dispensing through any channel

Step 2: Initiate Prior Authorization Proactively

Do not wait for a PA denial before gathering documentation. Initiate the PA process the same day as the prescribing visit. The most effective PA submissions include:

Complete medication history: all prior DMARDs with start/stop dates and documented reasons for failure

Current disease activity scores: DAS28-CRP or DAS28-ESR for RA; SALT score for alopecia areata

Lab results confirming eligibility: CBC, LFTs, TB screening results

Letter of medical necessity if the patient has a history of intolerance or contraindication to required step therapy agents

Step 3: Enroll Patients in the Olumiant Together Program

Eli Lilly's Olumiant Together program is specifically designed to bridge the gap between prescription and dispensing. The program provides:

Insurance verification and prior authorization support

Specialty pharmacy coordination and enrollment

Savings card enrollment for commercially insured patients ($5/month copay)

Patient assistance referrals for uninsured or underinsured patients

Your office can initiate enrollment on the patient's behalf. Call 1-844-658-6426 or visit olumiant.com/savings.

Step 4: Use medfinder to Find Available Specialty Pharmacies

When your patient has a prescription ready but is having difficulty locating a specialty pharmacy with Olumiant in stock, medfinder for providers can help. medfinder calls pharmacies in the patient's area and identifies which ones can fill the prescription — the results are sent directly to the patient via text. Integrating medfinder into your access workflow eliminates hours of manual phone calls for your care team.

Step 5: Build a Refill Reminder System

Patients on chronic Olumiant therapy for RA or alopecia areata frequently experience gaps in therapy because they underestimate specialty pharmacy lead time. Educate patients to:

Begin the refill process at least 10–14 days before their last dose

Set up automatic refills at their specialty pharmacy if available

Confirm annual PA renewal dates and add calendar reminders for both patient and staff

What to Do When Access Fails Despite Your Best Efforts

If your patient has exhausted all access channels and still cannot get Olumiant, consider clinical alternatives based on their indication. Upadacitinib (Rinvoq) and tofacitinib (Xeljanz) are comparable JAK inhibitors for RA; ritlecitinib (Litfulo) and deuruxolitinib (Leqselvi) are FDA-approved alternatives for alopecia areata. See our detailed provider shortage guide at Olumiant shortage: what providers need to know in 2026 for additional clinical context.